CS8 – TIMI 73a

CS8 TIMI 73a is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~152 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia. 

TIMI Website Ionis Study CS8

CORE CS8 – TIMI 73a on ClinicalTrials.gov

CONTACT US about CORE CS8 – TIMI 73a

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close